biostudies-literatureUnknown135(24)Niu G<h4>Background</h4>The study aimed to describe the aortic valve morphology in Chinese patients underwent transcatheter aortic valve replacement (TAVR) for symptomatic severe aortic stenosis (AS), and the impact of sizing strategies and related procedural outcomes.<h4>Methods</h4>Patients with severe AS who underwent TAVR were consecutively enrolled from 2012 to 2019. The anatomy and morphology of the aortic root were assessed. "Downsize" strategy was preformed when patients had complex morphology. The clinical outcomes of patients who performed downsize strategy were compared with those received annular sizing strategy. The primary outcome was device success rate, and secondary outcomes included Valve Academic Research Consortium-3 clinical outcomes variables based on 1-year follow-up.<h4>Chinese medical journal2968-2975https://www.ebi.ac.uk/biostudies/studies/S-EPMC10106152biostudies-literatureAnatomical morphology of the aortic valve in Chinese aortic stenosis patients and clinical results after downsize strategy of transcatheter aortic valve replacement.PMC10106152Ali WBRen XYao JZhang HJilaihawi HZhang LYe YSong GZhang QZhou ZLu BWang MLiu XZhao QAn YWang YNiu GWu YModine TfalseAnatomical morphology of the aortic valve in Chinese aortic stenosis patients and clinical results after downsize strategy of transcatheter aortic valve replacement.<h4>Background</h4>The study aimed to describe the aortic valve morphology in Chinese patients underwent transcatheter aortic valve replacement (TAVR) for symptomatic severe aortic stenosis (AS), and the impact of sizing strategies and related procedural outcomes.<h4>Methods</h4>Patients with severe AS who underwent TAVR were consecutively enrolled from 2012 to 2019. The anatomy and morphology of the aortic root were assessed. "Downsize" strategy was preformed when patients had complex morphology. The clinical outcomes of patients who performed downsize strategy were compared with those received annular sizing strategy. The primary outcome was device success rate, and secondary outcomes included Valve Academic Research Consortium-3 clinical outcomes variables based on 1-year follow-up.<h4>2022-01-01T00:00:00Z2022 Dec2025-04-04T07:34:55.608Z2025-04-04T07:34:55.608ZS-EPMC101061523672821310.1097/CM9.0000000000002517